Melyd

Glimepiride, the active ingredient in Melyd, is a second‑generation sulfonylurea presented as an oral tablet for oral use. It lowers blood glucose by stimulating insulin release and is indicated for the management of type 2 diabetes mellitus in adult patients. It is used as monotherapy or in combination with other antidiabetic agents to achieve glycemic targets.

GNH USA supplies Melyd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Glimepiride is used to improve glycemic control in the type 2 diabetes mellitus therapeutic pathway. - Type 2 diabetes mellitus (adult): lowers fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise in type 2 diabetes: enhances endogenous insulin secretion. - Combination therapy for type 2 diabetes: used with metformin or other agents to achieve target HbA1c.

Glimepiride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hypoglycemia: episodes of low blood sugar, especially with missed meals. - Weight gain: modest increase in body weight. - Nausea: mild gastrointestinal discomfort. - Headache: transient cranial pain. - Dizziness: sensation of light‑headedness. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe hypoglycemia: prolonged low glucose requiring medical intervention. - Allergic reactions: rash, itching, or swelling. - Stevens‑Johnson syndrome: severe skin eruption. - Blood dyscrasias: anemia or leukopenia. - Hepatic dysfunction: elevated liver enzymes.

When prescribing glimepiride, clinicians should consider several safety measures to minimize risk. - Blood glucose monitoring: check levels regularly to avoid hypoglycemia. - Renal impairment adjustment: reduce dose in patients with reduced kidney function. - Elderly patients: start with low dose and monitor closely. - Sulfonylurea allergy: avoid use in individuals with known hypersensitivity. - Concomitant medications: review other drugs that may affect glucose. - Store at room temperature: keep in original container, protect from moisture and heat.

Glimepiride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other sulfonylureas or meglitinides: additive hypoglycemic effect. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase glimepiride plasma levels. - MAO inhibitors: potential for unpredictable glucose changes.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Thiazide diuretics: can raise blood glucose. - ACE inhibitors or ARBs: may enhance antihyperglycemic effect. - NSAIDs: may affect renal function and glucose control.